Drug
Betahistine Mesylate tablet
Betahistine Mesylate tablet is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (66.7%)
Phase 41 (33.3%)
Trials by Status
recruiting125%
completed250%
not_yet_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Efficacy and Safety of Rimegepant for Acute Dizziness
NCT07435090
completedphase_4
Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo
NCT07075289
recruitingphase_2
Laser Acupuncture for Meniere Disease
NCT06544434
completed
Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
NCT06544590
Clinical Trials (4)
Showing 4 of 4 trials
NCT07435090Phase 2
Efficacy and Safety of Rimegepant for Acute Dizziness
NCT07075289Phase 4
Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo
NCT06544434Phase 2
Laser Acupuncture for Meniere Disease
NCT06544590
Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4